GlassScriptPhysician profile
Lorena L De Alejandro
NPI 1043720923
$2,736.26
in general payments reported to CMS, 2019-2025
25 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $382 · 2024: $934 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $258.14 | 2023-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $229.64 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $221.82 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $216.52 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $211.00 | 2023-2025 | Farxiga, Breztri |
| Boston Scientific Corporation | $190.65 | 2025 | Watchman Flx |
| Lilly USA, LLC | $177.90 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $167.57 | 2023-2025 | |
| Abbvie INC. | $139.69 | 2023-2025 | |
| Edwards Lifesciences Corporation | $139.51 | 2024 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $129.48 | 2023-2025 | |
| Amgen INC. | $129.26 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $102.28 | 2023-2025 | Octrode, Proclaim, Freestyle Libre 3 |
| Medtronic, INC. | $72.34 | 2023-2025 | Symplicity G3, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $71.90 | 2024-2025 | Pifeltro, Zerbaxa, Gardasil |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.18 | 2025 | Trelegy Ellipta, Arexvy |
| Insulet Corporation | $40.68 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.40 | 2024-2025 | Synjardy, Jardiance |
| Inspire Medical Systems, INC. | $31.10 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $27.40 | 2025 | Gemtesa |
| Exact Sciences Corporation | $26.55 | 2025 | The Cologuard Plus Collection Kit |
| Baxter Healthcare | $20.37 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Aimmune Therapeutics, INC. | $19.57 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.99 | 2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $14.32 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena De Alejandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.